A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

• Subscribe to CNBC PRO
• Subscribe to Investing Club
• Licensing & Reprints
• CNBC Councils
• Join the CNBC Panel
• Digital Products
• News Releases
• Closed Captioning
• Corrections
• About CNBC
• Internships
• Site Map
• Careers
• Help
• Contact

• News Tips

  Got a confidential news tip? We want to hear from you.

  Get In Touch

• CNBC Newsletters

  Sign up for free newsletters and get more CNBC delivered to your inbox

  Sign Up Now

  Get this delivered to your inbox, and more info about our products and services.

• Advertise With Us

  Please Contact Us

• Ad Choices
• Privacy Policy
• Your Privacy Choices
• CA Notice
• Terms of Service

© 2026 Versant Media, LLC. All Rights Reserved. A Versant Media Company.

Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.

Market Data Terms of Use and Disclaimers

Data also provided by